Large cell anaplastic lymphoma (Ki-1 lymphoma).
The "large cell anaplastic lymphoma, Ki-1 positive" is a recently described lymphoma subtype (about 1-8% of all NHL). Distinction from Hodgkin's disease and true histiocytic lymphoma/malignant histiocytosis is not always possible, even by experienced pathologists. It was recently incorporated in the updated Kiel Classification of lymphomas. Classical histologic appearance is a sinusoidal growth pattern in lymph nodes and presence of large bizarre anaplastic cells. Use of cell markers LCA, EMA and Ki-1 or Ber-H2 is essential for diagnosis. The mean age of patients is 50 years. Approximately 50% of patients have an advanced stage (III-IV). Prognosis depends on age and tumor localisations. Cutaneous involvement only is usually associated with a good prognosis. Median survival for patients with extra-cutaneous disease is 13 months. Treatment with intensive chemotherapy is usually needed. Long term remissions are more frequently seen in children and adolescents.
Ebo
D
D
Van Hoof
A
A
D000368:Aged; D015703:Antigens, CD / Q000302:isolation & purification; D000951:Antigens, Neoplasm / Q000302:isolation & purification; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D017730:Ki-1 Antigen; D016403:Lymphoma, Large B-Cell, Diffuse / Q000145:classification / Q000188:drug therapy / Q000473:pathology*; D009918:Orbital Neoplasms / Q000145:classification / Q000188:drug therapy / Q000473:pathology*; D011379:Prognosis
D015703:Antigens, CD; D000951:Antigens, Neoplasm; D017730:Ki-1 Antigen